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Abstract
It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and 
type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, 
blindness, amputations and kidney failure. Glucagon like Peptide-1 (GLP-1) is an effective insulinotropic agent and 
therefore its effects on insulin secretion have been greatly examined for more than two decades. It is a polypeptide 
hormone secreted by the intestinal L-cells into the blood in response to food uptake. GLP-1 has a very short half-life in 
vivo due to the rapid proteolytic degradation by Dipeptidyl Peptidase IV (DPP-IV). Therefore DPP-IV resistant GLP-1 
analogues, Exenatide and Liraglutide, have been developed and are currently being used in the treatment of type 2 
diabetes. GLP-1 agonist functions by binding to its receptor, GLP1R, on the cell surface.
The GLP-1R belongs to the class B peptide receptor family based on its structure and function. The binding of 
GLP-1 to its receptor results in activation of Gαs coupled adenylyl cyclase and the production of cyclic Adenosine 
Monophosphate (cAMP), which enhances glucose-induced insulin secretion. Continuous GLP-1R activation also 
causes insulin secretion and pancreatic islet β-cell proliferation and neogenesis. The GLP-1R is internalised following 
its activation, which regulates the biological responsiveness of the receptor.  Structurally the GLP-1R contains a 
large N-terminal extracellular domain (TM1-TM7) joined by three intracellular loops (ICL1, ICL2, ICL3) and three 
extracellular loops (ECL1, ECL2, ECL3), and an intracellular C-terminal domain. These domains play critical roles in 
GLP-1R trafficking to the cell surface, and also in agonist dependent activation and internalisation of the receptor. This 
review is focused on type 2 diabetes, its treatment with GLP-1, GLP-1R structure and function, and the physiological 
affects resulting from GLP-1R activation.
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Introduction 
The actions of Glucagon like peptide-1 (GLP-1) have been greatly 
examined over the last twenty years, due to the hormones effectiveness 
at lowering blood glucose levels and increasing insulin secretion in 
type 2 diabetic patients [1,2]. GLP-1 exerts its actions through the 
GLP-1 Receptor (GLP-1R), a family B G-Protein Coupled Receptor 
(GPCR) which mediates its effects through the Gαs subunit, which 
in turn activates Adenylyl Cyclase (AC). The involvement of Gαs 
and subsequent accumulation of cyclic Adenosine Monophosphate 
(cAMP) in glucose-induced insulin secretion is well established [3].
Type 2 Diabetes 
Background 
The World Health Organization describes diabetes mellitus as 
a “metabolic disorder of multiple actiology characterised by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action, 
or both” [4,5]. It was estimated that 366 million people (8.4% of the 
world’s adult population) lived with diabetes in 2011 [6]. This number 
will continue to rise and has been estimated to reach 439 million by 
2030 [7]. Diabetes remains the leading cause of blindness, end stage 
renal disease, lower limb amputation, and cardiovascular disease [8,9]. 
Diabetes mellitus is classified into four categories, type 1, type 2, other 
specific types and gestational diabetes (Table 1) of which type 2 is the 
most common form [4,5,10].
Pathophysiology and causes 
Insulin is a hormone that is secreted in response to food uptake 
to maintain glucose homeostasis. It is produced by the β-cells in the 
islet of Langerhans in the pancreas [11]. Synthesis occurs on the rough 
Endoplasmic Reticulum (ER) as preproinsulin, containing a signal 
peptide that is cleaved to form proinsulin (Figure 1). Proinsulin then 
Types Description and Subtypes
Type 1
β-cell destruction, usually leading to absolute insulin deficiency
Autoimmune
Idiopathic
Type 2
Ranging from predominantly insulin resistant with relative
insulin deficiency to a predominantly secretory defect with or
without insulin resistance
Other 
Specific
Types
Genetic defects of β-cell function
Genetic defects in insulin action
Diseases of the exocrine pancreas
Endocrinopathies
Drug- or chemical induced
Infections
Uncommon form of immune-mediated diabetes
Other genetic syndromes sometimes associated with
diabetes
Gestational
Diabetes
Carbohydrate intolerance resulting in hyperglycaemia of
variable severity with onset or first recognition during
pregnancy
Diabetes mellitus is classified into four categories, type 1, type 2, other specific 
types and gestational diabetes
Table 1: Aetiological classification of disorders of glycaemia.
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traffics through the trans golgi network and packaged into secretory 
vesicles until required [12]. The hydrolysis of dietary carbohydrates 
such as starch or sucrose within the small intestines results in the 
production of glucose that is then absorbed into the blood. An increase 
in glucose concentrations in the blood stimulates the release of insulin. 
Insulin has different effects depending on the target tissue; it either 
facilitates the entry of glucose into adipose and muscle tissue or 
stimulates the liver to store glucose as glycogen. If insulin is absent or in 
low concentrations within the body, insulin sensitive cells are unable to 
absorb glucose and therefore use other fuel sources such as fatty acids 
for energy. When blood glucose levels are low, insulin is not produced 
and instead glucagon is secreted, broken down and released as glucose 
[13,14].
In normal individuals, glucose homeostasis keeps glucose levels 
under control and within the normal range of 80 to 120 mg/100 ml 
(4.4-6.7 mM). For patients with diabetes, insufficient insulin release 
results in hyperglycemia and high blood glucose levels [14,15]. An 
absolute lack of insulin producing β-cells in the pancreas results in the 
development of type 1 diabetes [4,5,16]. In contrast, type 2 diabetes is 
a result of insulin dependent cells not being able to respond to insulin 
effectively, also known as insulin resistance [4,5]. It is being noticed 
that type 2 diabetes only develops in patients who are insulin resistant 
with the onset of β-cell dysfunction [17].
It is estimated that 60-90% of patients with type 2 diabetes are obese, 
and obesity itself can cause or aggravate insulin resistance [18]. There 
is a greater than 90-fold increase in developing type 2 diabetes if you 
are obese [19]. Body Mass Index (BMI) is defined as the individual’s 
body weight divided by the square of their height (kg/m2), and a BMI 
greater than 25 is overweight and above 30 is obese [20]. It is suggested 
that patients with type 2 diabetes aim for a BMI of 25 or below [21]. 
However, there is still a 2.4-fold increased risk of developing type 2 
diabetes in those who are of normal BMI (between 18.5 and 24.9) but 
have an increased percentage of body fat distributed in the abdominal 
region [22-24].
Diet, sedentary lifestyle and genetics all play a role in the 
development of type 2 diabetes [7,25,26]. The dietary intake of 
saturated fat, trans-fatty acids and total fats was considered risk factors 
in the development of type 2 diabetes. In contrast dietary fibres or 
non-starch polysaccharides were considered protective factors [25]. 
Low-fat vegetarian and vegan diets have the potential to be used for the 
management of type 2 diabetes because they are associated with weight 
loss; improve cardiovascular health and increase insulin sensitivity 
[27,28]. A cohort study evaluated the association of multiple lifestyle 
factors, including diet, physical activity, alcohol use, smoking habits 
and adiposity measures, with the risk of developing type 2 diabetes. It 
was found to be approximately 50% lower in individuals whose physical 
activity and dietary habits indicated low risk and approximately 80% 
lower in those whose physical activity, dietary habits, alcohol use 
and smoking habits all indicated low risk [24,29]. In addition, having 
relatives with type 2 diabetes substantially increases the chance of 
developing type 2 diabetes. The Insulin Receptor Substrate-1 (IRS-1) 
gene has been associated with type 2 diabetes, insulin resistance and 
hyperinsulinemia in a large scale study that screened 14,000 people all 
around the world [30].
Signs and symptoms 
Type 2 diabetes often develops slowly from a condition of pre-
diabetes, and symptoms may not be apparent for years [7]. The 
characteristic symptoms of type 2 diabetes including; dehydration, 
blurred vision, excessive thirst, polydipsia (increased fluid intake) 
and polyuria (excessive urine production); can develop because of 
hyperglycaemia. In diabetes, insulin producing β-cells are either 
partially or completely unable to use glucose as a fuel and therefore 
switch to using fat, carbohydrates and protein metabolism as a 
fuel source instead. This process requires more energy and leads 
to polyphagia (excessive eating), weight loss and lethargy [4,5,31]. 
Additionally, hyperglycaemia can lead to skin infection as a result of 
open and slow healing sores because it is more difficult for the body to 
heal itself [32].
Serious long-term complications of type 2 diabetes include nerve 
dysfunction, cardiovascular disease, microvascular damage, renal 
failure, blindness, impotence and poor wound healing and are a result 
of prolonged hyperglycaemia [4,5,33]. These complications may also 
occur if the disease is controlled inappropriately. Hypoglycemia is 
caused by inaccurately administered insulin. A shortage of insulin 
causes the body to switch to metabolising fatty acids and as a result 
produces ketone bodies. This response results in ketoacidosis and 
causes dehydration in addition to many of the symptoms and 
complications already described [34]. Another metabolic complication 
is known as hyperglycaemia hyperosmolar state and is the end 
result of sustained osmotic diuresis. It is characterised by severe 
hyperglycaemia, hyperosmolarity, and dehydration, but without the 
significant ketoacidosis hyperosmolar hyperglycemic state [34,35].
Diagnosis 
Diabetes is diagnosed by recurrent or persistent hyperglycaemia. 
This can be demonstrated by any of the following criteria: a fasting 
plasma glucose level of 7.0 mM; a single plasma glucose reading 
in excess of 11.1 mM; and an Oral Glucose Tolerance Test (OGTT) 
administered two hours after 75 g oral glucose with fasting plasma 
glucose concentrations in excess of 11.1 mM [4,5].
Glycosylation of haemoglobin (HbA1c) is primarily used as a 
treatment-tracking test and reflects average glucose levels over 8-12 
weeks [36,37]. Measurements can be performed at any time and 
there is no need for fasting. It is recommended that HbA1c be used 
to measure blood glucose control in both pre-diabetics and patients 
with diabetes. A reading of 6.5% HbA1c or above is used to diagnose 
diabetes [37]. OGTT or intravenous glucose tolerance tests are used 
Figure 1:Processing of Preproinsulin. The signal peptide sequence (23 amino 
acids) is removed from the N-terminus of preproinsulin by proteases. This forms 
three disulphide bonds producing proinsulin. Further proteolytic cleavage of 
proinsulin removes the C-peptide producing mature insulin. Redrawn from [12].
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to determine insulin response of the pancreas and degree of insulin 
resistance. However, it was noted that glucose administered orally 
promoted a significantly greater insulin response than glucose 
administered intravenously (Figure 2), although plasma glucose levels 
were the same [38-40]. Further, cross reactivity with partially degraded 
proinsulin and insulin may occur and as a result insulin measurement 
may be problematic. It is especially problematic in patients who have 
developed anti-insulin antibodies through administering animal 
insulin. As a result, C-peptide concentration has been used as a semi 
quantitative measure of β-cell secretory activity instead of insulin itself. 
C-peptide has a half-life 2.5 times longer than insulin and therefore 
higher concentrations exist in the peripheral circulation and levels 
fluctuate less [41].
Approaches and goals for the treatment of type 2 diabetes
More intensive glucose control, mainly determined by HbA1c 
levels, can delay or prevent the development and progression of 
serious complications in type 2 diabetics [33]. Initial treatment of type 
2 diabetes generally begins with non-pharmacological interventions 
such as diet, lifestyle and exercise. These interventions combined 
with antihyperglycaemic agents (such as metformin) are expected 
to improve blood glucose control. If an HbA1c level greater than 7% 
is not achieved within 2-3 months, then the recommended second 
stage is the addition of hypoglycaemic agents (such as sulfonylureas) 
or insulin injections to the treatment. Hypoglycaemic agents reduce 
plasma glucose levels by increasing insulin secretion, reducing insulin 
resistance and/ or delaying glucose absorption in the gut [42-44].
In many cases treatment with either antihyperglycaemic or 
hypoglycaemic agents is not usually enough to achieve adequate blood 
glucose control and therefore insulin therapy is intensified [42,45,46]. 
However, insulin therapy has a number of risks associated with it 
including, hypoglycaemia, weight gain, and increased risk of colorectal 
cancer [47]. These risk factors together with the route of administration 
(usually subcutaneous injection); contribute too many patients being 
reluctant to maintain intensive insulin therapy [48].
Consequently, these classic treatments are often unsatisfactory and 
there is an imperative need for new classes of glucose lowering agents. 
Recently, incretin-based therapies have been used in the treatment of 
type 2 diabetes; namely Exenatide and Liraglutide. These drugs have 
the ability to preserve normal physiological responses to food intake 
and improve glycaemic control.
GLP-1 Treatment for Type 2 Diabetes 
Incretin hormones 
Incretins are gastrointestinal hormones that contribute to 
postprandial insulin release [40,49]. GLP-1 and Glucose-dependent 
Insulinotropic Polypeptide (GIP) are two major incretins and are 
thought to be responsible for up to 70% of insulin secreted from the 
β-cells of the pancreas following food intake. This increase in insulin is 
called the ‘incretin effect’ and maintains glucose concentrations at low 
levels irrespective of the amount of glucose ingested. This is achieved 
by increasing the sensitivity of β-cells to glucose [50]. The ‘incretin 
effect’ has been shown to be either reduced or absent in type 2 diabetics 
due to the loss of insulinotropic activity of GLP-1 and GIP. However, 
more recently it’s been suggested that the secretion of GIP and GLP-1 is 
normal in type 2 diabetic patients [51]. This strongly suggests a role for 
incretin hormones or their actions in the treatment of type 2 diabetes 
[39,52-55].
The GIP gene is mainly expressed in K-cells and enterochromaffin 
cells of the proximal small intestine. GIP secretion is stimulated 
by enteral glucose, lipids and products of meal digestion in a 
concentration dependent manner [56]. In patients with type 2 diabetes, 
GIP concentrations after food intake are either normal or slightly 
elevated. GIP infusion does not reduce plasma glucose concentrations 
in patients with type 2 diabetes. As a result GIP has not been thought 
of as a suitable candidate for therapeutic development [57,58]. In 
contrast, patients with type 2 diabetes have decreased GLP-1 activity 
[53,55,59]. It is currently unknown whether reduced GLP-1 activity is 
a cause or consequence of diabetes. First degree relatives of patients 
with type 2 diabetes have normal GLP-1 activity in response to glucose, 
this suggests that a reduction in GLP-1 activity seen in type 2 diabetic 
patients is more likely acquired [60,61]. Additionally, GLP-1 is able 
to stimulate glucose-dependent insulin secretion in type 2 diabetic 
patients under hyperglycaemic conditions [54,62,63]. Furthermore, 
administration of exogenous GLP-1 to type 2 diabetic patients leads 
to normalisation of hyperglycaemic conditions [54,64,65]. As a result, 
GLP-1 based strategies appear an interesting and more suitable target 
for the treatment of type 2 diabetes [66].
Synthesis and secretion of GLP-1 
GLP-1 is 42 amino acids in length and is synthesised from the 
posttranslational modification of proglucagon, by Prohormone 
Convertase 1 (PC1) within the intestinal L-cells. PC1 is specific to 
GLP-1 production in the L-cells [67,68]. The proglucagon gene (Figure 
3A) is expressed in both the pancreatic α-cells and in the intestinal 
L-cells, but posttranslational processing differs in these two tissues [69-
71]. In the pancreatic α-cells (Figure 3B), proglucagon is processed to 
glucagon, Intervening Peptide-1 (IP1), Major Proglucagon Fragment 
(MPGF), and Glicentin-related Pancreatic C-peptide (GRPP) by 
Prohormone Convertase 2 (PC2) [68,72]. In the intestinal L-cells 
(Figure 3C), proglucagon is cleaved to GLP-1, Glucagon like Peptide-2 
(GLP-2), Intervening Peptide-2 (IP2), oxyntomodulin and glicentin 
by PC1 [73-75]. However, emerging evidence suggests that pancreatic 
α-cells can also adapt to produce GLP-1 with recombinant expression 
of PC1 [76-78].
In secretory vesicles, the first six amino acids of GLP-1 are cleaved 
from the N-terminus forming the bioactive peptides. Approximately 
80% of truncated GLP-1 forms the predominantly secreted GLP-
1 (7-36)-NH2 and the remaining 20% is released as GLP-1 (7-37) 
(Figure 3D) [79]. Both GLP-1 (7-36)-NH2 and GLP-1 (7-37) bind 
to the GLP-1R with similar affinity and shows similar potency [80]. 
GLP-1 is produced in response to food intake, in particular glucose 
Figure 2: The Incretin Effect in Healthy Subjects and Type 2 Diabetic 
Patients. Venous insulin levels after oral glucose load (50g/400ml) and during 
intravenous glucose in healthy subjects and type 2 diabetic patients. Redrawn 
from [39].
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and triacylglycerols, and lowers blood glucose levels [49,81]. In times 
of fasting, GLP-1 plasma concentrations are very low and can be 
lowered even further with administration of somatostatin in humans, 
suggesting there are some basal rates of secretion [69]. Typically, ‘total’ 
GLP-1 concentrations are about 5-15 pmol/l in basal state, rising to 
about 20-60 pmol/l after food intake [49]. The secretion of GLP-1 from 
L-cells increases in about 10 minutes after food intake, which is later 
than the ‘cephalic phase’ stimulation of insulin secretion. This suggests 
that neuronal signals generating insulin release does not influence 
GLP-1 secretion. Evidence suggests that the presence of nutrients in 
the gut and the interaction with the microvilli of L-cells are responsible 
for GLP-1 secretion [69].
In vivo, GLP-1 has a very short half-life of 1.5 minutes due to the 
rapid proteolytic degradation by enzyme Dipeptidyl Peptidase-IV 
(DPP-IV) [82-85]. This enzyme cleaves the active GLP-1 (7-36) to 
its inactive GLP-1 (9-36) form by removing two amino acids at the 
N-terminus of the peptide [86-88]. GLP-1 (9-36) and GLP-1 (9-37) 
(Figure 3D) have both been identified as products of GLP-1 cleavage 
by DPP-IV action in vitro and in vivo [84]. The degradation occurs so 
quickly that less than 25% of active GLP-1 that is secreted enters the 
portal vein prior to reaching the liver [89]. As a result, it is estimated 
that approximately 85% of circulating postprandial GLP-1 is either 
GLP-1 (9-36) or GLP-1 (9-37) [90].
Biological activities of GLP-1 
GLP-1 has several actions in various tissues and exerts its effects 
through its cell surface receptor, the GLP-1R (Figure 4). Structurally 
related members of the glucagon family of peptides such as GLP-2, 
glucagon and GIP do not bind the GLP-1R at physiologically relevant 
concentrations [69]. The human GLP-1R gene is transcribed in 
pancreatic islet, brain, heart, intestine, kidney, liver, lung and stomach. 
However, the actions of GLP-1 in fat and muscle most likely occur 
through indirect mechanisms and do not occur in many species [91-
94]. The expression of the GLP-1R is consistent with the roles of GLP-1 
in glucose homeostasis, β-cell proliferation, heart rate, food intake and 
appetite and even learning [91].
In the pancreas, GLP-1 increases insulin secretion from islet 
β-cells and suppresses glucagon secretion for islet α-cells, in a glucose 
dependent manner [95,96]. Additionally, GLP-1 has been shown to 
promote β-cell proliferation and neogenesis, while preventing apoptosis 
[97-99]. In the gastro intestinal tract, GLP-1 delays gastric emptying 
and acts as a postprandial satiety signal to the brain to suppress appetite 
and food intake [56,100]. Furthermore, GLP-1 plays an important role 
in the enteric and central nervous system. The release of GLP-1 is tightly 
regulated and involves the gut-to-brain and the brain-to-periphery axis 
[101-103]. Pharmacological applications of GLP-1 have demonstrated 
a number of positive affects in the cardiovascular system, suggesting 
GLP-1 may play an important role in that system [104]. Additionally, 
evidence suggests GLP-1 and its receptor may modulate components 
of the insulin signalling pathway and decrease hepatic steatosis in vitro 
[94].
Interestingly, evidence is emerging to suggest GLP-1 (9-36) and 
GLP-1 (9-37), the inactive forms of GLP-1, have insulin-like actions on 
heart, liver and vasculature and strongly reduce activity on the GLP-1R 
of β-cells. It has therefore been proposed that they may act through a 
novel signalling pathway by binding to a different cell surface receptor 
[105]. 
GLP-1 based therapies
The binding of GLP-1 to its receptor results in insulin secretion from 
pancreatic β-cells, making them an important target in the treatment of 
type 2 diabetes. The biological and pharmacological activities of GLP-1 
have been the basis for two type 2 diabetic therapies. The first therapy 
is based on the use of DPP-IV inhibitors to prevent the breakdown 
of GLP-1 from its active to inactive form [66]. The second therapy is 
based on the use of DPP-IV resistant GLP-1 mimetics that replicate the 
Figure 3: The Posttranslational Processing of Proglucagon and GLP-1. In the 
pancreas, proglucagon (A) is cleaved to glucagon, GRPP, IP1 and MPGF by 
PC2, which comprise amino acids 33-61, 1-30 and 72-158 of proglucagon, 
respectively (B). In the intestinal L-cells proglucagon is processed by PC3 
to GLP-1, GLP-2, IP2, oxyntomodulin and glicentin which are composed of 
amino acids 78-107, 126-158, 111-123 and 33-69 of proglucagon respectively 
(C). GLP-1 (7-37) and GLP-1 (7-36) amide are the active forms of GLP-1 in 
the body, both are quickly degraded by DPP-IV into inactive GLP-1 (9-37) 
and GLP-1 (9-36) amide, respectively, as indicated (D). The cleavage site is 
indicated by the arrow.
Figure 4: Biological Activities of GLP-1. The main action of GLP-1 occurs at 
the pancreas where GLP-1 stimulates insulin secretion and inhibits glucagon 
secretion in a glucose dependent manner. In addition, GLP-1 also decreases 
appetite, slows gastric emptying, increases β-cell proliferation, increases 
cardiac function as well as other physiological actions as indicated in the 
diagram. Redrawn from [91].
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physiological actions of the native GLP-1 peptide but with a longer half-
life. DPP-IV, also named adenosine deaminase complexin G-protein 
or CD26 (cluster of differentiation 26), is an antigenic enzyme. It is 
associated with signal transduction, immune regulation and apoptosis 
and therefore is expressed on the surface of most cell types. DPP-IV is 
highly specific and cleaves between X-proline and X-alanine dipeptides 
(where X is any amino acid) at the N-terminus, but is unable to cleave 
peptides with a third proline (for example glycine-proline-proline) 
[84]. DPP-IV inhibitors increase GLP-1 levels by 2-3 fold over 24 hours 
by inhibiting 90% of plasma DPP-IV activity in vivo. They also have an 
additional advantage of oral administration [106]. There are currently 
three DPP-IV inhibitors, saxagliptin, sitagliptin and vildagliptin, used 
in the treatment of type 2 diabetes in Europe [107]. These inhibitors 
significantly decrease postprandial glucose levels and HbA1c by 0.5-
1.0% [66,108]. Sitagliptin and vildagliptin have been shown to improve 
β-cell function and reduce systolic blood pressure [109]. However, the 
long-term inhibition of DPP-IV may have adverse effects because this 
enzyme is expressed in many types of tissues and has many functions 
[110]. Experimental evidence has demonstrated an increase in infection 
and some tumours, supporting adverse immunological and oncological 
effects after prolonged use of DPP-IV inhibitors [111].
The main limitation of GLP-1 is a very short half-life (1.5 minutes) 
due to the rapid proteolytic degradation of GLP-1 by DPP-IV, cleaving 
the active GLP-1 (7-36) to the inactive GLP-1 (9-36) form [82,83,85]. 
DPP-IV cleaves GLP-1 between alanine and glutamic acid at positions 
8 and 9. A substitution at position 8 from alanine to valine (Ala8Val) 
stabilises the peptide without affecting it activity and prevents 
peptide degradation. However, the half-life of the modified peptide 
is still too short (4-5 minutes) to be used as a drug [112]. As a result 
therapeutic strategies that activate the GLP-1R and improve GLP-1 
actions have been extensively studied and developed. This has led to 
the development of two DPP-IV resistant GLP-1R agonists, Liraglutide 
and Exenatide. Liraglutide is a long-acting GLP-1 analogue with 97% 
sequence homology to human GLP-1 [113]. It is chemically similar to 
human GLP-1 but with structural modifications resulting in resistance 
to GLP-1 inactivation by DPP-IV and prolonged duration of action 
[114]. Liraglutide has a half-life of approximately 11-13 hours and it is 
administered once a day irrespective of meal times [115]. Exenatide is a 
peptide found within the salivary glands of the Gila monster lizard and 
has 52% sequence homology to GLP-1 [116]. It is also not enzymatically 
degraded by DPP-IV and therefore has a prolonged in vivo half-life 
of 3.4-4 hours compared with GLP-1. As a result it is administered 
twice daily within 60 minutes of a meal [117]. Both GLP-1R agonists 
are currently in use as drugs for the treatment of type 2 diabetes, as 
they are effective insulinotropic agents regulating blood glucose levels 
by increasing insulin secretion and supressing glucagon secretion in 
a glucose dependent manner [118,119]. Liraglutide and Exenatide 
significantly reduce both fasting and postprandial glucose levels and 
HbA1c levels by 0.8-1.5% [113]. The most common side effects of 
GLP-1 strategies are dyspepsia or nausea, which may lead to delayed 
gastric emptying. However, the effects seem to subside with continuous 
administration [66,120]. Acute pancreatitis has been reported in a few 
rare cases but their clinical significance remains unclear [121]. These 
side effects associated with the long-term administration of these 
peptides have necessitated the search for orally active small molecule 
agonists of the GLP-1R [122].
A series of eleven-amino acid peptide, agonists of the GLP-1R, 
have been reported to have excellent potency and in vivo activity in 
ob/ob mouse models of diabetes [123,124]. These peptides are closely 
related structurally to nine C-terminal residues of GLP-1 but are 
substituted with several unnatural amino acids at position 11, such 
as homohomophenylalanine. This gives rise to the opportunity to 
increase stability against proteolytic degradation by DPP-IV. However, 
the activity of these peptides can be blocked with inactive exendin (9-
39) (exendin antagonist) [124].
The GLP-1R in Type 2 Diabetes 
Characterisation of the GLP-1R 
Regulation of GLP-1R expression and function is clinically 
important because of its role in GLP-1 based therapy for type 2 
diabetes. The GLP-1R belongs to a group of receptors known as GPCRs 
(also named seven transmembrane receptors). They are the largest 
family of cell surface receptors and are the most common target for 
medical therapeutics due to their involvement in many physiological 
and pathological processes. Over 50% of drugs available on the market 
act on GPCRs [125]. All GPCRs are made up of a single polypeptide 
chain of up to 1100 amino acid residues, which pass through the 
plasma membrane seven times. This membrane topology results in 
an extracellular N-terminal domain, seven transmembrane α-helices 
joined by three Extracellular Loops (ECL) and three Intracellular Loops 
(ICL) followed by an intracellular C-terminal domain that interacts 
with G proteins (Figure 5). GPCRs are classically divided into three 
classes: A, B and C based on their sequence homology and functional 
similarities [126].
The GLP-1R belongs to the family B GPCRs, also known as 
the secretin receptor family and is made up of only 15 members 
[126,127]. This family is distinguishable from the other two families 
by the large N-terminal extracellular domain that is 100-160 amino 
acids in length and has an important role in agonist binding (Figure 
5B). Additionally, this family contains several conserved disulphide 
bonds in the N-terminus of the receptor, which stabilises the large 
N-terminal structure [127]. The gene encoding the GLP-1R is located 
on the short arm of chromosome 6 (6p21) and encodes a 463 amino 
acid length protein (Figure 6) [128-130]. The GLP-1R is predicted to 
contain a large hydrophilic N-terminal extracellular domain with a 
putative signal peptide, seven hydrophobic transmembrane domains 
(TM1-TM7) joined by three hydrophilic ICL (ICL1, ICL2, ICL3) and 
three ECL (ECL1, ECL2, ECL3); ending in an intracellular C-terminal 
domain (Table 2) [131].
Following GLP-1 binding to the GLP-1R, the receptor undergoes 
a conformational change and transmits extracellular signals through 
heterotrimeric G-proteins (Figure 7). Heterotrimeric G-proteins are so 
called because they interact with Guanosine Diphosphate (GDP) and 
Guanosine Triphosphate (GTP) [132]. Heterotrimeric G-proteins are 
made up of α, β, and γ subunits and can activate or inhibit a number of 
effectors. The α subunit (Gα) consists of an α-helical domain that binds 
guanine nucleotides, and a GTPase domain that binds and hydrolyses 
GTP. The Gα subunit has been categorised into four families based 
on similarities within their primary sequence: Gαs, Gαi/o, Gαq/11, 
Gα12/13. The β and γ subunits are bound in a complex (Gβγ) through 
an N-terminal coil on the Gγ subunit to the base of the Gβ subunit. 
The Gβγ subunit binds to hydrophobic pocket in the Gα subunit in 
the inactive state [132]. Agonist-occupied GPCRs activate Gα, which 
dissociates from Gβγ. The GLP-1R has been shown to activate members 
of the Gαs, Gαi/o and Gαq/11 [133,134]. Members of the Gαs family 
activate AC, increasing cAMP levels and in turn activate both Exchange 
Protein Activated by cAMP (EPAC) and Protein Kinase A (PKA) 
[135]. Activating members of the Gαi/o family inhibit AC activity and 
regulate inward rectifier potassium channels [136]. Gαq/11 family 
Citation: Thompson A, Kanamarlapudi V (2013) Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clin Exp Pharmacol 3: 
138. doi:10.4172/2161-1459.1000138
Page 6 of 18
Volume 3 • Issue 4 • 1000138
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal GPCR Signalling & Diabetic Complications
Figure 5: Structure of GPCRs. All GPCRs share a common membrane topology 
consisting of an NH2-terminal extracellular domain, seven transmembrane 
α helices joined by three ECL and ICL and an intracellular COOH-terminal 
domain. Red circles denote conserved residues. (A) The Family A GPCRs 
contain a disulphide bridge that connects ECL1 and ECL2 causing the 
receptor to ‘kink’ and ‘tilt’. The C-terminal domain contains a conserved 
palmitoylated cysteine residue. (B) The Family B GPCRs are characterized by 
a long N-terminal tail consisting of many conserved disulphide bonds. (C) The 
Family C GPCRs have very large N and C- terminal domains with an agonist 
binding domain described as a ‘venus fly trap’ located at the N- terminus. 
Additionally, a conserved disulphide bridge connects ECL1 and ECL2 and a 
short and conserved ICL3 also define family C GPCRs. Redrawn from [246].
Figure 6: Amino acid Sequence of the Human GLP-1R. The signal peptide 
is highlighted in red circles (1-23). Residues in yellow highlight conserved 
cysteine residues that form disulphide bonds. Residues in blue show amino 
acid important in agonist binding. Amino acids that have a structural role 
are highlighted in orange. Glycosylation sites are shown in grey. Residues 
important in receptor internalization are shown in purple and for activation and 
functions are in green. Redrawn and adapted from [1].
SP= Signal peptide; NT= N-terminal domain; CT= C-terminal domain
Table 2: The amino acid sequence of the GLP-1R domains.
Amino Acids
Length (from-to)
Description Amino Acids
Length (from-to)
Description
23 (1-23) Putative SP 122 (24-145) NT
23 (146-168) TM1 8 (169-176) ICL1
20 (177-196) TM2 31 (197-227) ECL1
25 (228-252) TM3 12 (253-264) ICL2
24 (265-288) TM4 15 (289-303) ECL2
26 (304-329) TM5 22 (330-351) ICL3
21 (352-372) TM6 15 (373-387) ECL3
21 (388-408) TM7 55 (409-463) CT
members activates Phospholipase C (PLC) which in turn hydrolyses 
phosphatidylinositol-4,5-bisphophate to Inositol-1,4,5-triphosphate 
(Ins(1,4,5)P3; IP3) and Diacylglycerol (DAG). DAG activates Protein 
Kinase C (PKC) and IP3 induces intracellular calcium release from 
the ER [137]. Gα12/13 family members regulate intracellular actin 
through Rho GTPase activity [138]. The Gβγ complex can also 
activate a number of intracellular signalling molecules and pathways 
including phospholipases and phosphatidylinositol 3-kinase, Ras, Raf, 
Extracellular signal-regulated Kinase (ERK) and ion channels, but it 
role in GLP-1R activation is not fully known [136,139].
After stimulation with agonist, most GPCRs internalise from 
the cell surface to dampen the biological response, resensitisation of 
the system or propagation of the signal through novel transduction 
pathways. Agonist induced GPCR internalisation typically occurs in 
a clathrin-dependent fashion via GRKs (GPCR kinases), β-arrestins 
and ADP-ribosylation Factor (ARF) proteins (Figure 8) [140,141]. 
Currently, there is some confusion by which pathway the GLP-1R is 
internalised. It has been reported that clathrin-coated vesicles mediate 
GLP-1R internalisation and three PKC phosphorylation sites within the 
C-terminal tail are important for this to occur (Figure 6) [142]. However, 
more recently it has been shown that the GLP-1R is internalised by 
caveolae-mediated endocytosis upon agonist stimulation (Figure 9). 
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A feature of GPCRs that are endocytosed via caveolae is their ability 
to bind caveolin-1, a protein weighing approximately 21-24 kDa. 
Caveolin-1 is the principle component of caveolae and can interact 
with a number of signalling molecules including receptor tyrosine 
kinases, G proteins and GPCRs. This occurs via a common caveolin-
binding motif, ΦXΦXXXXΦ and ΦXXXXΦXXΦ, where Φ is an 
aromatic residue and X is any amino acid [143,144]. Endocytosis in this 
manner can lead to fission of caveolae enriched vesicles and then fusion 
with caveosomes, large intermediate intracellular organelles [145]. The 
GLP-1R was reported to contain a classical caveolin-1 binding motif, 
247EGVYLYTLLAFSVF260, in ICL2 (Figure 6) [146].
Recently, there has been increasing interest in the stoichiometry of 
GPCRs and how this impacts receptor function [147,148]. For family B 
GPCRs, homodimerisation has been shown to occur with the calcitonin 
receptor [149)], secretin receptor [150] and parathyroid receptor [151]. 
There is also interest in the development of allosteric agonists and 
whether they interact with a single receptor (in cis) or across dimers 
(in trans). Currently, most drug development is dependent on an in 
cis conformation and mechanism of action [152,153]. The GLP-1R has 
been shown to form a homodimer through an interface along TM4 
and is required for receptor signalling. Alanine substitutions to Leu256, 
Val259 or Gly252, Leu256, Val259 abolished GLP-1 binding, reduced cAMP 
and ERK signalling and abolished calcium signalling. Dimerisation of 
the GLP-1R was important for signal bias and discriminated between 
peptide and non-peptide activation. Additionally, dimerisation was not 
required for allosteric modulation by compound 2 demonstrating that 
this small molecule agonist acted in cis [152].
Allosteric modulation of the GLP-1R 
Many GPCRs have been shown to have allosteric binding sites 
that are spatially and often functionally distinct to the primary agonist 
(orthosteric) binding site (Figure 10) [154,155]. Small molecule 
Figure 7: Activation and Inactivation of Heterotrimeric G-Proteins through 
GPCRs. Prior to agonist binding, the Gαβγ complexes are associated with 
each other. GDP is bound to the Gα subunit rendering it inactive. Upon agonist 
binding, the Gα subunit dissociates from the Gβγ complex and GTP binds 
the Gα subunit, initiating signalling events. After signal transduction, GTP is 
hydrolyzed back to GDP by Gα-GTPase and the Gα subunit associates with 
the Gβγ complex.
Figure 8: Clathrin-Dependent Internalisation of GPCRs. The proposed 
model for GPCR internalisation is based on the β2-adrenoceptor receptor. 
Upon agonist binding, GPCRs are phosphorylated by GRKs, this leads to 
the recruitment of arrestin and subsequent ARF6 activation. The activation of 
ARF6 results in the promotion of clathrin, AP-2 and Src to form clathrin-coated 
pits. Finally, dynamin causes the ‘pinching off’ of vesicles from the plasma 
membrane into the cytosol.
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allosteric agonists can either increase or decrease the binding efficiency 
of an orthosteric agonist. Such agonists are generally termed positive 
allosteric modulators or negative allosteric modulators depending 
on what effects they have on the receptor [156]. Allosteric sites 
may provide novel therapeutic targets and a number of advantages 
compared to classical orthosteric agonists. This is advantageous where 
selective orthosteric therapy has been difficult, for example, where the 
orthosteric site is highly conserved. Targeting the allosteric sites allows 
for greater selectivity to be obtained [157,158]. Additionally, allosteric 
agonists may provide a second advantage in that they can be selectively 
regulated by endogenous agonists [158]. Finally, low molecular weight 
agonists that have the potential for oral administration can be used 
to target allosteric binding sites [154]. Some small molecule agonists, 
named ago-allosteric agonists, can bind to the receptor and can act as 
both agonists and allosteric modulators in the absence of orthosteric 
agonists. It is unknown how these agonists affect the binding or 
efficiency of compounds acting at the orthosteric site. Compounds 
with allosteric or ago-allosteric properties increase the potential for 
receptor subtype selectivity. This allows for more improved, targeted 
and novel therapeutics [159]. Receptor internalisation and signalling 
mediated by ago-allosteric agonism may provide further information 
into the activation and regulation of this receptor.
A small molecule GLP-1R agonist, compound 1 (2-(2’methyl) 
thiadiazolylsulfanyl-3-trifluoromethyl-6,7-dichloroquinoxaline) 
(Figure 11A), has demonstrated low-affinity, low potency allosteric 
agonism to the GLP-1R. In an effort to produce a more potent agonist, 
compound 2 was developed (6,7-dichloro-2- methylsulfonyl-3-N-tert-
butylaminoquinoxaline) (Figure 11B). Compound 2 is an ago-allosteric 
agonist that not only increases the affinity of GLP-1 for its receptor, 
but also acts as an agonist. Additionally, exendin (9-39) antagonist 
did not inhibit compound 2 binding, showing a second binding site 
on the GLP-1R distinct from the orthosteric binding site [160]. The 
effectiveness of compound 2 to stimulate insulin secretion has also been 
assessed in vivo. Although, compound 2 was able to stimulate insulin 
secretion it was unable to do so as effectively as GLP-1, Liraglutide or 
Exenatide. Further, combining compound 2 with either Liraglutide or 
Exenatide did not show a substantial improvement in insulin secretion 
response in mice [161]. Two additional small molecule agonists of the 
GLP-1R, compound A (4-(3,4-dichlorophenyl)-2-(ethanesulfonyl)-
6-(trifluoromethyl)pyrimidine) and compound B (4-(3-(benzyloxy)
phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)), have also demonstrated 
ago-allosteric properties (Figure 11C and 11 D). Like compound 2, these 
compounds induced cAMP signalling and increased insulin secretion 
in rat islets and animal studies. Further studies showed treatment with 
compound B to near-normalise insulin secretion with human islets 
isolated from a donor with type 2 diabetes [162]. These small molecule 
agonists indicate a useful starting point for the identification and 
design of orally active allosteric GLP-1R compounds.
Figure 9: Caveolae-Dependent Internalisation of GPCRs. The proposed 
model for caveolae mediated endocytosis. Upon agonist binding a number of 
signaling pathways are activated. This results in the recruitment of caveolin, 
forming a vesicle from the plasma membrane that that enters into the cytosol.
Figure 10: Binding Models of Orthosteric and Allosteric Agonists of Class 
B GPCRs. (A) The general peptide (orthosteric) binding model for class B 
GPCRs is shown. The C-terminal region of the orthosteric peptide binds 
to the N-terminal region of the GPCR. This results in a weak interaction 
and consequently causes the formation of a bi-tethered confirmation. (B) 
Non-peptide (allosteric) binding and antagonist model for class GPCRs. 
Non-peptide/ antagonist (blue circle) binds the receptor and causes a 
conformational change that prevents peptide binding. This non-peptide 
interaction can either block peptide stimulated receptor signaling or may not 
affect peptide binding to the N-terminal domain of the GPCR. Redrawn from 
[153].
Figure 11: Small Molecule Allosteric Agonists of the GLP-1R. The chemical 
structures of (A) compound 1, (B) compound 2, (C) compound A and (D) 
compound B are depicted.
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An alternative model for agonist induced activation 
An alternative model for agonist induced activation of family B 
GPCRs has been proposed. It has been suggested that upon binding 
of an orthosteric agonist to the receptor, the N-terminal domain of the 
receptor undergoes a conformational change and interacts with another 
region of the receptor, which results in GPCR activation (agonism) 
[163]. This hypothesis originally arose from observations with the 
Corticotropin-releasing Hormone Receptor (CRHR; also known as 
corticotropin-releasing factor receptor), another family B GPCR. 
Nuclear Magnetic Resonance (NMR) analysis of the CRHR showed 
agonist induced conformational changes where the C-terminal region 
of the agonist binds the N-terminal domain of the receptor, which in 
turn causes the N-terminus to dock with the transmembrane bundle 
[164]. Additionally, similar conformational changes were noticed with 
the secretin receptor where secretin peptides with minor modifications 
to the N-terminus were no longer able to interact with the receptor, 
but still resulted in full agonism [165]. These findings could not be 
explained by current agonist binding models of family B GPCRs. 
Further, it was shown that the synthetic peptide corresponding to a 
conserved sequence in the N-terminal region of the secretin receptor, 
Trp48-Asp49-Asn50 (WDN), acts as a full agonist and docks where the 
top of TM6 continued onto the ICL3 in the secretin receptor [166]. 
This suggests that the N-terminal domain of the secretin receptor folds 
to allow a ‘built in agonist’ to interact with the transmembrane bundle 
[167]. More recently, a synthetic peptide encoding an N-terminal 
sequence of the GLP-1R, Asn63-Arg64-Thr65-Phe66-Asp67 (NRTFD), was 
shown to have full agonist activity. Further, this peptide was also able to 
activate the secretin and vasoactive intestinal peptide type 1 receptors 
because it was able to form an intradomain salt bridge between side 
chains of arginine and aspartate in ECL3 above TM6, similar to the 
WDN peptide. Moreover, GLP-1 (9-37) antagonist failed to block the 
NRTFD action, confirming that the site of action of NRTFD peptide is 
different from that of endogenous agonist GLP-1 [168].
The GLP-1R N-terminal domain and its signal peptide
Approximately 15% of GPCRs show evidence of a signal peptide 
sequence that is often critical for synthesis and processing of the 
receptor [169]. This signal peptide sequence is usually located in the 
N-terminal domain of the protein. It is about 20 amino acids in length 
and contains a run of hydrophobic residues. The first stage of protein 
targeting is insertion into the ER by binding to the Signal Recognition 
Particle (SRP). This is usually mediated by a signal peptide sequence 
within the N-terminal domain of the protein [170]. Two types of 
signal peptide sequences can be observed. One group contains a signal 
peptide sequence that is cleaved by a signal peptidase and is required 
for ER targeting and insertion. The second group possesses a non-
cleavable anchor sequence within the first transmembrane domain for 
this process. Interestingly, the ER targeting and insertion of GPCRs can 
occur in either manner but the majority have a non-cleavable anchor 
sequence. Subsequently, the mature receptor is subjected to further 
post-translational modifications in the Golgi prior to translocation and 
insertion into the plasma membrane [171].
Cleavage of the signal peptide sequence is not essential for all 
GPCRs that contain them. Deleting the signal peptide sequence of the 
thyrotropin receptor abolished functionality [172,173]. However, the 
corticotropin-releasing factor receptor type 2a signal peptide although 
present, was found to be incapable of mediating ER targeting [174,175]. 
The GLP-1R has been shown to contain a cleavable N-terminal signal 
peptide that is essential for receptor processing and trafficking to the 
cell surface (Figure 6). A mutation to the signal peptide cleavage site 
(Ala21Arg) still allowed receptor synthesis but prevented cleavage and 
resulted in receptor retention within the ER [176]. It is unclear why 
some GPCRs require a cleavable signal sequence and other do not. 
Statistical analysis suggests that the length of the N-terminal domain 
and the number of positively charged residues it contains denotes the 
presence of a cleavable signal peptide sequence [171].
The GLP-1R has six highly conserved cysteine residues at the 
N-terminal domain, highlighting their structural importance. These 
cysteine residues form disulphide bonds between Cys46 and Cys71, 
Cys62 and Cys104, and between Cys85 and Cys126 [177] (Figure 6). 
Additionally, Asp67, Trp72, Pro86, Arg102, Gly108, and Trp110 are six other 
residues that are highly conserved across family B GPCRs, of which 
Trp72 and Trp110 have been shown to be important in GLP-1R agonist 
binding [1,178,179]. The crystal structure of the GLP-1R extracellular 
domain has shown these conserved residues to be positioned centrally. 
For example, Asp67 is centrally located and forms intermolecular 
interactions directly with Trp72 and Arg121 and indirectly interacts 
with Arg102 via a water molecule. Asp67 interacts with Tyr69 and Ala70. 
Arg102 is sandwiched between the side chains of Trp72 and Trp110. These 
interactions, and Gly108, stabilise the receptors N-terminal domain. 
Pro86 plays a critical role in forming the agonist binding site (Figure 
6) [180]. In addition to the two highly conserved tryptophan residues, 
Trp72 and Trp110, already mentioned. Substitution of Trp39, Trp72, Trp91, 
Trp110, or Trp120 by alanine in the full-length rat GLP-1R abolished 
GLP-1 binding, whereas substitution of Trp87 had no effect on agonist 
binding [178]. The role of Trp33 still remains unclear. Trp120 has no 
role in agonist binding but instead plays a structural role by forming 
a hydrophobic cluster with Phe80, Tyr101, Phe103 and Leu111 (Figure 6) 
[180].
Residues Thr29-Val30-Ser31-Lys32 also located within the N-terminal 
domain have been shown to confer peptide specificity. A mutation to 
this region of the GLP-1R resulted in a 7-fold decrease in GLP-1 affinity 
showing its importance in agonist binding (Figure 6) [181].
N-linked glycosylation of the GLP-1R 
The GLP-1R has been shown to undergo N-linked glycosylation 
[182,183]. GPCRs are synthesised in the ER and require translocation 
to the Golgi. In this trafficking process, GPCRs undergo post- or co-
translational modifications including glycosylation, methylation, 
phosphorylation, sulfation and lipid addition. It is likely that 
glycosylation may play an important role in cell surface trafficking and 
receptor maturation [184,185].
N-linked glycosylation usually occurs in the ER, which adds a 
glycan core unit (Glucose3-Mannose9-N-acetylglucosamine2) to an 
asparagine residue within a sequence of asparagine-X-serine/ threonine, 
where X can be any amino acid but proline [186-188]. Terminal glucose 
residues are cleaved by glucosidases and oligomannoses are formed 
(Figure 12A) [189]. During trafficking of glycoproteins from the ER to 
the Golgi, glycans can be extensively modified to form either complex 
or hybrid N-glycans (Figure 12B and C) [188,190]. Hybrid N-glycans 
are formed in the medial Golgi and are due to the incomplete actions 
of α-mannosidase II. Hybrid N-glycans are unable to be processed to 
complex N-glycans [190]. O-linked glycosylation that occurs within the 
Golgi is not very well understood. The process involves the addition of 
N-acetyl-galactosamine to serine or threonine residue and may occur 
at any residue with no sequence protein [191,192]. Glycans can be 
cleaved with the use of enzymes. PNGase F cleaves between asparagine 
and N-acetylglucosamine residues on oligomannoses and both hybrid 
and complex N-glycans. Endo H cleaves between N-acetylglucosamine 
residues on oligomannoses and some hybrid glycans (Figure 12).
Citation: Thompson A, Kanamarlapudi V (2013) Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clin Exp Pharmacol 3: 
138. doi:10.4172/2161-1459.1000138
Page 10 of 18
Volume 3 • Issue 4 • 1000138
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal GPCR Signalling & Diabetic Complications
O-linked glycosylation has been shown to occur in the V2 
vasopressin receptor [193] and δ-opioid receptor [194]. However, 
most GPCRs undergo N-linked glycosylation but the role of this 
varies between receptors. The rat GLP-1R has previously been 
demonstrated to undergo N-linked glycosylation [195,196]. Further, 
the N-terminal domain of the human GLP-1R contains three N-linked 
glycosylation sites at positions Asn63, Asn82 and Asn115 [182,183]. 
Tunicamycin, an inhibitor of N-linked glycosylation, interfered with 
GLP-1R biosynthesis and trafficking and abolished agonist binding. 
Further, mutations to Asn63, Asn82 and Asn115 with leucine were made 
individually and in combination. Individual mutations did not affect 
receptor cell surface expression or agonist binding. However, mutations 
of two or three residues resulted in complete loss of GLP-1 binding. 
Immunofluorescence staining of the mutant receptors transfected cells 
demonstrated that the mutant receptors were still synthesised but were 
localised to the ER or Golgi [182,183].
ICLs , ECLs and TM domains of the GLP-1R 
The ICLs of GPCRs are known to interact with G-proteins and 
play a role in receptor activation [197]. For the GLP-1R, ICL3 has been 
shown to mediate signalling via G-proteins. However, ICL1 and ICL2 
have demonstrated an importance in discriminating between different 
types of G-proteins. ICL1 and ICL3 specifically mediate Gαs whereas 
ICL2 activates Gαs, Gαi/o and Gαq/11 [134]. An alanine substitution at 
Arg176 within ICL1, caused a reduction in GLP-1 mediated stimulation 
of cAMP but had no effect on receptor expression or internalisation 
(Figure 6) [198]. Additionally, different domains of ICL3 have been 
shown to be responsible for the Gαs and Gαi/o activation. The entire 
ICL3 (amino acids 329-351) has been shown to prefer Gαs over Gαi/o. 
However, the C-terminal end of ICL3 (amino acids 329-341) stimulates 
both Gαs over Gαi/o subtypes. Further, the N-terminal end of ICL3 
(amino acids 341-351) also stimulates both subtypes, but favours Gαs 
over Gαi/o [133]. Residues important in coupling to G-proteins are 
mainly located in ICL3 and where TM5 meets ICL3 [199]. Alanine 
substitutions to Val327, Ile328 or Val331, where TM5 meets ICL3, caused 
significantly lowered cAMP production but had no effect on receptor 
expression (Figure 6). These residues and Lys334 form a hydrophobic 
face that interacts directly with the G-protein [198]. A single block 
deletion of Lys334-Leu335-Lys336 within the N-terminal half of ICL3 
caused a significant decrease in cAMP production in response to GLP-
1, of which Lys334 showed most significance with no effect on receptor 
expression (Figure 6). This indicated that the region was required to 
couple Gαs and stimulate AC [199]. A glycine substitution to Arg348, 
near the C-terminal end of ICL3, nearly abolished cAMP production 
and decreased receptor affinity in response to GLP-1 (Figure 6) [200].
The ECLs of GPCRs have been shown to be important in agonist 
binding and receptor trafficking. A disulphide bridge between ECL1 
and ECL2 is conserved across all GPCRs and has been suggested to 
be involved in stabilising the receptor during agonist binding [160]. 
Residues within TM2 and ECL1 appear to be more important in GLP-1 
binding than exendin-4 binding [87,201]. Mutations within ECL1 of 
the GLP-1R (Lys197, Asp198, Lys202, Met204, Tyr205, Asp215 or Arg227) have 
been shown to decrease agonist binding affinity (Figure 6) [87,179,201]. 
The GLP-1R has a number of conserved amino acids within ECL2 
including Lys288, Asp293, Cys296, Trp297 and Trp306. These residues 
were demonstrated to be essential for GLP-1R function because 
alanine mutations resulted in a significant loss of GLP-1 binding and 
attenuation of receptor signalling [202,203]. Mutations within ECL2 
have been shown to affect GLP-1 binding and efficiency, indicating an 
important role in GLP-1R activation. Interestingly, some mutations 
resulted in distinct changes in pathway responses. For example alanine 
substitutions to Cys296, Trp297, Arg299, Asn300, Asn302, Tyr305 and Leu307 
increased signal bias towards ERK activation. However, an alanine 
mutation at Trp306 abolished all biological activity (Figure 6). Scanning 
alanine substitutions were made on ECL2 of the GLP-1R and the effect 
of GLP-1, exendin-4 and oxyntomodulin was assessed (Figure 6). 
Mutations at positions Glu292, Cys296 and Asn300 resulted in a greater 
potency of exendin-4 but reduced oxyntomodulin efficacy possibly 
because the receptor is unable to form an active ternary complex. Met303 
appeared to play a role in cAMP signalling and was more important 
for exendin-4 and oxyntomodulin than GLP-1. When positions Lys290, 
Tyr291 and Glu294 were mutated, a significant loss in GLP-1 calcium 
signalling was witnessed and no affect was seen when stimulated with 
oxyntomodulin. In cAMP formation, Arg299 and Lys307 mutations had a 
reduced potency for GLP-1 than exendin-4 suggesting exendin-4 cAMP 
signalling required the distal portion of ECL2. Exendin-4 mediated 
calcium responses were abolished in mutations at Asp293, Arg299, Tyr305 
and Lys307 yet reduced but measurable responses were observed with 
GLP-1 suggesting subtle difference in calcium signalling mechanisms. 
Figure 12: Structure of Common N-glycans. N-linked glycosylation at the 
ER involves the addition of oligosaccharides to asparagine residues within a 
sequence of asparagine-X-serine/ threonine. (A) Terminal glucose residues 
are cleaved by glucosidases and oligomannoses are generated. During 
trafficking of glycoproteins from the ER to the Golgi, glycans can be extensively 
modified to form either (B) hybrid or (C) complex N-glycans. The cleavage 
sites of glycosidase enzymes PNGase F and Endo H are indicated. Asn= 
Asparagine; Fuc= Fructose; Gal= Galactose; GlcNAc= N-acetylglucosamine; 
Man= Mannose; Ser= Serine; Thr= Threonine; X= any amino acid except 
proline.
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Cys296, Arg299 and Tyr305 mutants demonstrated no detectable calcium 
signalling and increased ERK signalling. Collectively, these mutations 
have suggested that GLP-1, exendin-4 and oxyntomodulin activate the 
receptor using different mechanisms [203]. The ECL3 of the GLP-1R 
has originally been hypothesised to act as an endogenous agonist [166]. 
However, this hypothesis was disproven when it was recognised that 
ECL3 could not establish necessary spatial approximation with the 
agonist binding region of the GLP-1R [204]. The GLP-1R has recently 
been shown to bind an agonist peptide (NRTFD), corresponding to 
the sequence of the GLP-1R, Asn63-Asp67, at the N-terminal region of 
ECL3 [168,205]. Furthermore, ECL3 has been shown to be important 
for endogenous agonist action of several members of family B GPCRs, 
suggesting that this region is likely to be important for drug binding 
[206-208].
Residues of TM1 through to TM3 are also important for agonist 
binding and receptor function. For example, a missense mutation of 
Thr149 in TM1 reduced agonist binding [209]. Additionally, substitution 
of His180 by arginine in TM2 resulted in a reduction in both the potency 
of cAMP production and affinity of the receptor for GLP-1 (Figure 
6) [200]. A positively charged Lys288 in TM4 is highly conserved in 
all family B GPCRs and has been demonstrated to be important for 
the interaction of GLP-1 to its receptor (Figure 6). Further, Lys288 has 
been hypothesised to be important in stabilising the top of TM4 [202]. 
Substitution of Lys288 by neutral leucine or alanine also reduced the 
affinity of GLP-1 for its receptor. However, substitution with a positively 
charged arginine had very little effect, demonstrating a positive charge 
was essential at this particular location [210]. Additionally, mutating at 
Lys288 resulted in a reduced binding affinity of GLP-1 than exendin-4 
[203,210]. For some GPCRs such as the GLP-1R, serine and threonine 
rich amino acid sequences in TM3 or the cytoplasmic domain are 
required for receptor internalisation [142,211,212].
The C-terminal tail in agonist induced internalisation 
The C-terminal domain of GPCRs is known to interact with 
intracellular proteins involved in receptor internalisation. There are 
three regions that are involved including: a region just downstream 
of TM7; the very end of the C-terminus; and the region in between 
(Figure 13) [213]. The C-terminal domain plays a critical role in agonist 
induced internalisation, desensitisation, down regulation and arrestin 
signalling [214].
The first region is called the helix-8 and is an α-helix that terminates 
with palmitoylated cysteine residues. It is located just downstream 
of TM7 and has been shown to associate with a number of proteins 
(Figure 13) [213]. For example the dopamine receptor interacting 
Figure 13: Interacting Proteins of the C-terminus of GPCRs. Diagram representing the three regions of the C-terminal domain known to interact with intracellular 
proteins. The first region is called the helix-8 and is an α-helix that terminates with palmitoylated cysteine residues. The second includes the PDZ domain and is located 
at the very end of the C-terminal domain. And the region in between that is known as ‘binding sites with GPCR interacting proteins’. Redrawn from [213].
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protein 78 binds to a conserved sequence located in the helix-8 domain 
of the dopamine D1 receptor and is responsible for receptor trafficking 
to the plasma membrane [215].
At the very end of the C-terminal domain, many GPCRs possess 
a PDZ binding domain that plays a role in receptor targeting, 
internalisation, recycling and signalling (Figure 13) [216]. The PDZ 
binding domains are grouped into three classes based on their amino 
acid sequences [217,218]. GPCRs without a PDZ binding domain 
have shown to interact with other proteins through the extreme 
C-terminus. For example the C-terminus of the rhodopsin receptor 
was also reported to interact with ARF4 [219]. The GLP-1R lacks this 
PDZ binding domain. The region between helix-8 and the very end of 
the C-terminus is referred to as ‘binding sites with GPCR interacting 
proteins’ (Figure 13) [213]. A PxxP motif within the C-terminus of 
thee β3-adrenergic receptor interacts with the Src Homology (SH) 3 
domain of Src and results in the activation of ERK [220]. In addition, 
the extreme of TM7 close to the C-terminal domain is also known to 
interact with other proteins. An NPxxY motif within the serotonin 
5-hydroxytryptamine receptor 2a interacts with ARF1 and couples to 
phospholipase D in a G-protein independent manner [221].
GPCRs including the GLP-1R regulate intracellular effector 
proteins such as PLC and AC via heterotrimeric G-proteins. Upon 
high or sustained levels of agonist stimulation, G-protein mediated 
responses typically desensitise [222]. Desensitisation occurs by either 
an agonist specific response (homologous desensitisation) or activation 
of a different receptor (heterologous desensitisation). Receptor 
phosphorylation and arrestins mediate receptor desensitisation and 
cause uncoupling from G-proteins [223]. Additionally, GPCRs are 
phosphorylated at regions of the C-terminal domain in response 
to agonist binding [224]. The C-terminal domain of GPCRs is also 
required for targeting to endosomes, Golgi and the cell surface. These 
motifs are four to six amino acids in length and contain a critical 
tyrosine residue and follow a general consensus of YXXΦ, where Y is 
a tyrosine residue, X denotes any amino acid and Φ is a hydrophobic 
residue [225-227].
The last 33 amino acids of the C-terminal domain of the GLP-1R 
containing serine 441/442, 444/445 and 451/452 phosphorylation sites 
were required for efficient receptor activation and therefore internalisation 
(Figure 6) [142,228]. Interestingly, receptor internalisation was quickened 
when amino acids 408EVQ410 were substituted with alanine at the C-terminal 
domain of the GLP-1R [229].
 GLP-1R signal transduction in pancreatic β-cells 
In β-cells, the main action of GLP-1 through the GLP-1R is the 
formation of cAMP and its insulinotropic activity [69]. Upon agonist 
binding, the Gαs subunit dissociates from the receptor, couples to 
AC and generates cAMP [122,230]. When blood glucose levels rise, it 
enters the β-cell through GLUT1 and GLUT2 transporters. Glucose 
is phosphorylated by glucokinase to glucose-6-phosphate, and results 
in the ATP/ ADP ratio in the cytosol increasing and the plasma 
membrane depolarising by closing KATP channels. The closure of 
KATP channels, in turn opens calcium channels, releasing intracellular 
stores of calcium. The increase of cytosolic calcium causes secretory 
granules containing insulin to fuse to the plasma membrane and 
insulin is exocytosed [231,232]. It is also likely that human glucokinase 
activity is more important in glucose-induce insulin secretion than the 
rate at which glucose enters the β-cell [233].
GLP-1 has been shown to increase the quantity of insulin secreted 
per cell and cause more β-cells to become more sensitive to increased 
glucose levels by GLP-1 modulated KATP channels [234,235]. 
Activation of GLP-1 can also increase calcium concentration by 
partial activation of L-type voltage dependent calcium channel and/ or 
increase calcium-induced calcium release from intracellular stores and 
is mediated by PKA phosphorylation in an ADP-dependent manner 
[69]. The release of intracellular stores of calcium is achieved by one of 
two ways: either due to PKA activation or EPAC activation [236,237]. 
It has been suggested that PKA activation is achieved through the IP3 
receptor (PKA dependent) and EPAC activation is achieved through 
ryanodine receptors (PKA independent) [238,239].
The increase in calcium levels causes an exocytotic response and is 
potentiated by elevated cAMP levels due to an increase in the amount 
of vesicles available for release [58]. In pancreatic β-cells, there are three 
different pools of insulin secretory vesicles. A reserve pool is situated 
in the cytoplasm; a readily release pool and immediately release pool 
are situated close to the membrane. GLP-1 increases the amount of 
insulin secretory vesicles in the readily release pool. GLP-1 depolarises 
the cell membrane closing KATP channels and therefore the current is 
inactivated before the cell can begin repolarising. Consequently, the cell 
does not reach its resting membrane potential and starts to depolarise 
before it has recovered from inactivation [240].
Additionally, a sustained increase in cAMP induced nuclear 
translocation leads to the activation of cAMP Response Element 
Binding-protein (CREB) and cell proliferation. The phosphorylation of 
PKA is said to activate CREB, interact with Transducer of Regulated 
CREB activity (TORC2), increase insulin receptor substrate-1 
expression and cause activation of a serine-threonine protein kinase, 
Akt [241]. Akt has been described to link GLP-1 signalling to β-cell 
growth and survival [242]. Furthermore, the activation of Ribosomal 
protein S6 (rbS6) in animal models has been reported as a key regulator 
of glucose homeostasis and β-cell mass [243].
Two mutations within the GLP-1R have been shown to alter 
insulin secretion. In a Japanese study, one patient diagnosed with type 
2 diabetes had a missense mutation that resulted in the substitution of 
Thr149 with methionine [244]. The patient exhibited impaired glucose 
tolerance, insulin secretion and sensitivity. The mutated receptor 
had reduced affinity in vitro for GLP-1 and exendin-4 [209]. Further, 
GLP-1R mutants lacking Lys334-Leu335-Lys336 of ICL3 in the HIT-T15 
insulinoma cell line showed an absence of GLP-1 induced cAMP 
production, calcium channel activation and insulin secretion [245].
Conclusions and Future Prospects 
The ability of GLP-1 to lower postprandial hyperglycemia by 
increasing insulin secretion and inhibiting glucose secretion makes 
this peptide an ideal candidate for the treatment of type 2 diabetes. 
Additionally, as GLP-1 is able to retain its glucose lowering activity in 
patients with type 2 diabetes it is also of significant clinical relevance. 
The main limitation of GLP-1 is a very short half-life and as a result 
therapeutic strategies that activate the GLP-1R and improve GLP-1 
actions have been extensively studied and developed.
GLP-1R activation by GLP-1 has many beneficial effects, most 
likely due to the activation of a number of signalling pathways upon 
agonist binding. But the precise signalling pathway that is activated and 
is critical for GLP-1 to exert its affects on the β-cell it still unknown. 
Therefore, agonists that act through the GLP-1R would be the perfect 
treatment in type 2 diabetes. However, only Liraglutide and Exenatide 
are currently available and have a number of severe side effects. As a 
result, there is a need for small molecule agonists that have a longer 
half-life and are orally active. It is also important to note that receptor-
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agonist interactions are more complex than was previously believed. 
Some GPCRs do not function as monomers and can be regulated by 
more than one agonist and can also ‘self activate’. This knowledge is 
important for further agonist development of GPCRs. Overall a lot 
sill remains to be determined in GLP-1R pharmacology and drug 
development in the treatment of type 2 diabetes.
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